PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $8 | $19 | $42 | $56 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $9 | $7 | $9 |
| Total Curr. Assets | $12 | $28 | $49 | $65 |
| Property Plant & Equip (Net) | $11 | $11 | $12 | $12 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $11 | $11 | $12 | $12 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $22 | $39 | $61 | $78 |
| Liabilities | – | – | – | – |
| Payables | $6 | $7 | $13 | $9 |
| Short-Term Debt | $5 | $6 | $5 | $6 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $1 | $2 | $2 | $1 |
| Other Curr. Liab. | $12 | $7 | $8 | $6 |
| Total Curr. Liab. | $25 | $22 | $28 | $21 |
| LT Debt | $1 | $1 | $2 | $4 |
| Deferred Rev, NC | $7 | $7 | $8 | $8 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $107 | $111 | $116 | $95 |
| Total NC Liab. | $115 | $119 | $126 | $107 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $140 | $141 | $154 | $128 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$420 | -$403 | -$392 | -$349 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $302 | $300 | $299 | $298 |
| Total Equity | -$117 | -$102 | -$93 | -$50 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $22 | $39 | $61 | $78 |
| Net Debt | -$2 | -$12 | -$34 | -$47 |